Roger Danclar
Internal Medicine · Crystal River, FLNPI 1558380139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,500 and has fallen 91.7% since, to $125 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$637
- Novo Nordisk$611
- Lilly USA, LLC$467
- Bayer$454
- Gilead$454
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,263 |
| GSK | 30 | $637 |
| Novo Nordisk | 26 | $611 |
| Lilly USA, LLC | 24 | $467 |
| Bayer | 19 | $454 |
| Gilead | 17 | $454 |
| Fresenius USA Marketing, Inc. | 15 | $265 |
| Amgen | 12 | $244 |
| Sanofi-aventis U.S. LLC | 10 | $213 |
| CSL Behring | 9 | $199 |
| Merck | 9 | $157 |
| Boehringer Ingelheim | 7 | $156 |
| Exact Sciences | 5 | $98 |
| Johnson & Johnson | 4 | $89 |
| Insulet Corporation | 3 | $61 |
| Phadia US Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Inari Medical, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Althera Pharmaceuticals LLC | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| AbbVie | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,765 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 50 | $54,471 |
| EliquisApixaban | 35 | $39,927 |
| JardianceEmpagliflozin | 27 | $38,573 |
| XareltoRivaroxaban | 29 | $33,349 |
| FarxigaDapagliflozin Propanediol | 32 | $29,270 |
| OzempicSemaglutide | 19 | $26,589 |
| EntrestoSacubitril/Valsartan | 19 | $24,055 |
| TrulicityDulaglutide | 15 | $14,124 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,500 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,108 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $4,082 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 39 | $4,057 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,824 |
| Duloxetine Hcl | 69 | $3,521 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $3,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $467 | $68,59465 claims |
| Boehringer IngelheimJardiance | $156 | $38,57327 claims |
| AstraZenecaFarxiga, Symbicort | $1,263 | $34,37850 claims |
| Johnson & JohnsonXarelto | $89 | $33,34929 claims |
| Novo NordiskOzempic | $611 | $26,58919 claims |
| GSKTrelegy Ellipta | $637 | $12,50012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Crystal River
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.